Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The majority of its operations are in the Middle East and North Africa region, the United States and Europe. The Company�s operations span over 45 countries and focuses on a range of therapeutic areas. On October 3, 2011, it completed the acquisition of 63.9% of Societe de Promotion Pharmaceutique du Maghreb S.A. (Promopharm). On May 2, 2011, the Company completed the acquisition of Baxter Healthcare Corporation�s Multi-Source Injectables (MSI) business. On January 6, 2012, the Company acquired an additional 9.8% interest in Promopharm, bringing the total ownership to 94.1%. On July 14, 2011, the Company incorporated a subsidiary Savanna Pharmaceuticals Industries Co. Ltd.